Triad of acute infusion-related reactions associated with liposomal amphotericin B: Analysis of clinical and epidemiological characteristics

被引:65
作者
Roden, MM
Nelson, LD
Knudsen, TA
Jarosinski, PF
Starling, JM
Shiflett, SE
Calis, K
DeChristoforo, R
Donowitz, GR
Buell, D
Walsh, TJ
机构
[1] NCI, Pediat Oncol Branch, Immunocompromised Host Sect, Bethesda, MD 20892 USA
[2] NIH, Dept Pharm, Ctr Clin, Bethesda, MD 20892 USA
[3] Univ Virginia, Charlottesville, VA USA
[4] Fujisawa Healthcare, Deerfield, IL USA
关键词
D O I
10.1086/374553
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We investigated the clinical characteristics and treatment of patients with a distinctive triad of acute infusion-related reactions (AIRRs) to liposomal amphotericin B (L-AMB) via single-center and multicenter analyses. AIRRs occurred alone or in combination within 1 of 3 symptom complexes: (1) chest pain, dyspnea, and hypoxia; (2) severe abdomen, flank, or leg pain; and (3) flushing and urticaria. The frequency of AIRRs in the single-center analysis increased over time. Most AIRRs (86%) occurred within the first 5 min of infusion. All patients experienced rapid resolution of symptoms after intravenous diphenhydramine was administered. The multicenter analysis demonstrated a mean overall frequency of 20% (range, 0%-100%) of AIRRs among 64 centers. A triad of severe AIRRs to L-AMB may occur in some centers; most of these reactions may be effectively managed by diphenhydramine administration and interruption of L-AMB infusion.
引用
收藏
页码:1213 / 1220
页数:8
相关论文
共 19 条
[1]   PULMONARY TOXICITY DURING INFUSION OF LIPOSOMAL AMPHOTERICIN-B IN 2 PATIENTS WITH ACUTE-LEUKEMIA [J].
ARNING, M ;
HEERSONDERHOFF, AH ;
WEHMEIER, A ;
SCHNEIDER, W .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1995, 14 (01) :41-43
[2]  
Bishara J, 2001, ANN PHARMACOTHER, V35, P308, DOI 10.1345/aph.10240
[3]   Allergic reaction to the liposomal component of liposomal amphotericin B [J].
Cesaro, S ;
Calore, E ;
Messina, C ;
Zanesco, L .
SUPPORTIVE CARE IN CANCER, 1999, 7 (04) :284-286
[4]   DOUBLE-BLIND RANDOMIZED STUDY OF THE EFFECT OF INFUSION RATES ON TOXICITY OF AMPHOTERICIN-B [J].
ELLIS, ME ;
ALHOKAIL, AA ;
CLINK, HM ;
PADMOS, MA ;
ERNST, P ;
SPENCE, DG ;
THARPE, WN ;
HILLIER, VF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (01) :172-179
[5]   CLINICAL-STUDIES OF LIPOSOME-ENCAPSULATED DOXORUBICIN [J].
GABIZON, A ;
ISACSON, R ;
LIBSON, E ;
KAUFMAN, B ;
UZIELY, B ;
CATANE, R ;
BENDOR, CG ;
RABELLO, E ;
CASS, Y ;
PERETZ, T ;
SULKES, A ;
CHISIN, R ;
BARENHOLZ, Y .
ACTA ONCOLOGICA, 1994, 33 (07) :779-786
[6]  
GALLIS HA, 1990, REV INFECT DIS, V12, P308
[7]   PRETREATMENT REGIMENS FOR ADVERSE EVENTS RELATED TO INFUSION OF AMPHOTERICIN-B [J].
GOODWIN, SD ;
CLEARY, JD ;
WALAWANDER, CA ;
TAYLOR, JW ;
GRASELA, TH .
CLINICAL INFECTIOUS DISEASES, 1995, 20 (04) :755-761
[8]  
Groll AH, 1998, ADV PHARMACOL, V44, P343, DOI 10.1016/S1054-3589(08)60129-5
[9]  
Johnson MD, 1998, PHARMACOTHERAPY, V18, P1053
[10]   CARDIOPULMONARY TOXICITY AFTER LIPOSOMAL AMPHOTERICIN-B INFUSION [J].
LEVINE, SJ ;
WALSH, TJ ;
MARTINEZ, A ;
EICHACKER, PQ ;
LOPEZBERESTEIN, G ;
NATANSON, C .
ANNALS OF INTERNAL MEDICINE, 1991, 114 (08) :664-666